Just 6 weeks after seeing disappointing data from its Phase III study of tasquinimod for prostate cancer, Sweden’s Active Biotech is laying off 47 staffers, leaving only 9 employees at the company.

…read more

Source: PhIII prostate cancer failure forces deep job cuts at Active Biotech


0 No comments